The strongest genetic risk factor of systemic lupus erythematosus (SLE), HLA-DRB1*03:01, generates an abnormal protein that, in the presence of the pro-inflammatory interferon gamma (IFN-gamma), activates SLE-related genes and triggers SLE-characteristic cellular, tissue, and immune abnormalities. These are the findings of a new study in lab-grown human and mouse immune cells,…
Treatment with ustekinumab leads to significant reductions in severe flares in systemic lupus erythematosus (SLE) patients with active disease, 1-year data from a Phase 2 trial shows. Biomarker analyses of the same data also provided clues about how ustekinumab works in SLE. The data were presented at the…
Transplanting regulatory T-cells — cells that suppress the immune system — resolved skin inflammation in a patient with systemic lupus erythematosus, Phase 1 clinical trial results show. The study, “Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus,” was published in the journal Arthritis &…
Interferon-gamma, an endogenous regulator of immune responses, is associated with reduced cerebral volume in lupus patients, a new Brazilian study shows. The study, “Interferon-γ Is Associated with Cerebral Atrophy in Systemic Lupus Erythematosus,” appeared…
A study published in the Journal of Experimental Medicine demonstrates that a particular cell-signalling protein is crucial for the formation of autoreactive B-cells in systemic lupus erythematosus (SLE), but not for the formation of B-cells fighting infections. The finding of this autoimmune mechanism opens up the possibility for the development…